Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
  • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
  • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
  • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
  • A61K49/10—Organic compounds
  • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
  • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms

Definitions

• the present invention relates to a new class of amphiphilic compounds with a diazepine-derivative as paramagnetic metal ion chelating unit and their use as MRI contrast agents.
• a variety of chelating agents in the form of complex with metal ions are kn own in the a rt, for the use as contrast agent, pa rticu l a rly as M RI (magnetic resonance imaging) contrast agents, whereby the metal ion is a paramagnetic metal ion (see e.g. EP0292689).
• Said complexes are characterised by peculiar values of relaxivity (rl).
• the relaxivity is an intrinsic property of the paramagnetic complexes, useful to predict their ability to increase the nuclear magnetic relaxation rate of vicinal water protons. It has been observed, in fact, that the higher the relaxation rates, the more enhanced the contrast imaging properties of the compounds are.
• WO00/30688 discloses a class of amphipatic polyamino-polycarboxylic chelating agents and paramagnetic metal complexes thereof as M RI contrast agents, particularly useful for the blood pool imaging, characterised in having a tetra-aza cyclic or a tri-aza linear backbone.
• WO03/008390 general ly refers to a series of multidentate aza ligands, either linear or cyclic, variously functionalised and able to complex a paramagnetic metal ions such as Fe 2+ , Gd 3+ or Mn 2+ .
• the present invention refers to a new class of derivatives of formula (I), or a pharmaceutically acceptable salt thereof:
• the invention provides a process for the preparation of the present compounds of formula (I) or a pharmaceutical acceptable salt thereof:
• R MV are as above defined and L is the l in ker comprising a terminal carboxylic function
• step b) amidation reaction between the product of step b) and the Y group as herein defined;
• the invention refers to a derivative of formula (I) in the form of a complex with a paramag netic metal ion, useful as contrast agent for MRI analysis.
• compositions comprising a chelate derivative of formula (I), o r a pharmaceutical salt thereof, in the form of a complex with a paramagnetic metal ion in admixture with one or more physiologically acceptable carriers or excipients.
• Said compositions are useful in particular as MRI contrast agent e.g. as blood pool agents, for the imaging of blood micro circulation in tumour or as contrast agent for angiography.
• compositions are used in a method for imaging body regions com prisi ng ad m i n isteri ng to a su bject to be i maged a d iag nostical ly effective amount of the composition of the invention.
• the present invention refers to a method for operating an imaging system, preferably MRI system, comprising the steps of:
• the present i nvention refers to a method of diagnosis comprising the administration of a n effe ct i ve d ose of a composition of the invention to the human or animal body, examining the body with a diagnostic device and compiling data from the examination .
• said method of diagnosis is a MRI method .
• linear or branched Ci-C 6 alkyl group means a linear or branched chain comprising from 1 to 6 carbon atoms such as: methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl, hexyl and the like.
• linear or branched Ci-Cio and Ci-C 2 o alkyl group mean a linear or branched chain comprising from 1 to 10 or from 1 to 20 carbon atoms
• Ci-C 30 alkyl group means a linear or branched chain comprising from 1 to 30 carbon atoms.
• aliphatic C 3 -Ci 0 cyclic or heterocyclic group optionally substituted means a carbon cyclic ring having from 3 to 10 carbon atoms, optionally interrupted by one or more heteroatoms such as : N, S, or O.
• Such aliphatic cyclic groups can be isolated (i.e. not embedded in other rings) or fused to o ne o r m ore ri n g to co nstitute a po lycyclic moiety.
• any heteroatom with free unsatisfied valences is assumed to have hyd rogen atom to fulfil the valences.
• Non limiting examples of aliphatic C3-C10 cycl ic g roups are : cyclopropane, cyclobutane, cyclopentane, cyclohexane and the like.
• Non limiting examples of aliphatic C 3 -Ci 0 heterocyclic groups are: pyrrolidine, piperidine, dioxane, and the like.
• aromatic C 6 -Ci 0 cyclic or heterocyclic group optionally substituted means an aromatic carbon cyclic ring having from 6 to 10 carbon atoms, optionally interrupted by one or more heteroatoms such as: N, O or S.
• Such aliphatic cyclic groups can be isolated (i.e. not embedded in other rings) or fused to one or more ring to constitute a polycyclic moiety.
• Non limiting examples of aromatic C 6 -Ci 0 cyclic groups are : benzene, toluene, xylene, naphthalene, and the like.
• Non limiting examples of aromatic C 6 -Ci 0 heterocyclic groups are: pyridine, piperazine, thiophene, imidazole, pyrazole, pyrrole, furane, indole and the like.
• oxycarbonyl-(d-C 3 o)alkyl means a group of formula -0(CO)- (Ci- C 3 o)alkyl, wherein (Ci-C 30 )alkyl is as above defined .
• -(d-C 6 )alkylcarboxy group means a group wherein a divalent (Ci- C 6 )alkyl group is bonded to a carboxylic group of formula -COORi, wherein Ri is as above defined .
• pharmaceutical acceptable means that the carrier, diluent excipients and/or salt should be compatible with the other ingredients of the formulation.
• complex or “paramagnetic complex” comprises with in its meaning an adduct between a chelating moiety or ligand and a metal or paramagnetic metal ion respectively.
• the chelating moiety comprises at least one donor atom bound to the central metal ion.
• a formula with chemical bonds shown as solid lines and not as wedges or dashed lines contemplates each possible isomer, e.g . each enantiomer and diastereoisomer, and a mixture of isomers such as racemic mixture.
• the compounds herein described can contain one or more asymmetric centres and thus potentially give rise to diastereoisomers and optical isomers.
• the present invention includes all such possible diastereoisomer as well as their racemic mixtures, their su bstantia l ly pu re resolved enantiomers, al l possible geometric isomers, and pharmaceutical acceptable salts thereof.
• the present invention refers to a new class of derivatives of Formula (I), or a pharmaceutical acceptable salt thereof:
• the Y group has the formula :
• Y' 2 -N- wherein preferred Y' residues are the same and are selected in the group consisting of: a Ci-C 20 alkyl chain, preferably a C 2 -Ci 5 alkyl chain, even more preferably selected from : C 4 H 9 , C 6 Hi 3 , C 8 Hi 7 , Ci 0 H 2 i and Ci 2 H 25 .
• Y has the formula : Y'-NH- , wherein Y' is a linear alkyl group having 4 to 6 carbon atoms, interrupted by one or more group of formula :
• Y is a phospholipid having the formula : Y'-NH- wherein Y' is a C 2 -C 6 alkyl group, interrupted by one or more group of formula :
• Y can also be a monophosphate ester of a substituted or partially substituted glycerol, having at least one functional group of said glycerol esterified by a saturated or unsaturated aliphatic fatty acid, and the other two functions of the phosphoric acid being either free or in the form of a salt with an alkaline or earth-alkaline metal.
• Y is selected
• the linker L is a divalent group which connects the diazepine moiety to the Y group, thus providing a proper distance that can be suitably selected.
• the linker L is a carbonyl-alkyl derivative selected from: an optionally substituted Ci-C 6 linear alkyl group derivative and a cycloalkyl C 6 -C 8 residue, having a carbonyl function at the terminal side connected to the Y group.
• preferred linkers L are: methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl and linear or cyclic hexylcarbonyl. Even more preferably, the linker L is selected from:
• # indicates the point of attachment to the diazepine core of the derivative of formula (I) of the invention.
• the linker L is bound at one side to the Y group, and on the other side to the diazepine core.
• the Y group of formula Y'-NH- or (Y') 2 -N- presents a term i n a l n itroge n ato m a n d preferably, the linker L is bound to Y through the secondary -NH- nitrogen atom, or equally preferably, via the tertiary -N- nitrogen atom, as part of an amidic functionality.
• preferred L-Y- systems are selected from :
• the present invention refers to a new class of derivatives and pharmaceutical acceptable salts thereof, according to a formula (I) and selected from the group consisting of:
• R MV are as herein defined.
• the groups R 1 , R 11 , R m and R IV are preferably a carboxylic derivative or a salt thereof, e.g . groups of formula : -R 2 -COOR 1 or -R 2 -COO " M +
• R 2 is a bon d or a Ci-C 6 alkyl residue
• Ri is as above defined , preferably hydrogen
• M + is a counterion, e.g . a metal ion.
• the R 2 group is a bivalent radical selected from : methylene, ethylene, propylene and butylene, being methylene more preferred.
• the groups R MV are, the same, a carboxymethyl group of formula -CH 2 -COOH or -R 2 -COO " M + as formerly defined, whereby, preferred compounds of formula (I) of the invention have the following general formula ( ) :
• the invention relates to the compounds of the formula (I) or a pharmaceutical salt thereof as extensively herein described, in the form of a complex with a paramagnetic metal ion, preferably selected from : Gd(III), Mn(II), Cr(III), Cu(II), Fe(III), Pr(III), Nd(III), Sm(III), Tb(III), Yb(III), Dy(III) , H o(III) a nd Er(III) , whereas Gd (III ) and Dy(III) are particularly preferred .
• a paramagnetic metal ion preferably selected from : Gd(III), Mn(II), Cr(III), Cu(II), Fe(III), Pr(III), Nd(III), Sm(III), Tb(III), Yb(III), Dy(III) , H o(III) a nd Er(III) , whereas Gd (III ) and Dy(III) are particularly preferred .
• paramagnetic amphiphilic complexes can be prepared by analogy with other known procedures used in the art for the preparation of paramagnetic metal complexes, such as reaction of the precursor derivative of formula (I) with the metal of choice, the latter e.g . in the form of oxide, chloride or acetate, in a suitable solvent, typically water (for a general reference see WO00/30688) or even in organic solvent/water mixtures, typically depending on the sou rce of meta l ion employed .
• a suitable solvent typically water (for a general reference see WO00/30688) or even in organic solvent/water mixtures, typically depending on the sou rce of meta l ion employed .
• compound of formula (I), also when in the form of amphiphilic complex as above explained, are generally in the form of a salt with physiolog ical ly accepta ble bases or physiolog ica l ly acceptable ions of organic or inorganic acids.
• preferred bases are selected from : primary, secondary, tertiary amines, basic amino acids and inorganic hydroxides of sodium, potassium, magnesium, calcium or mixture thereof.
• Preferred anions of organic acid are: acetate, succinate, citrate, fumarate, maleate, oxalate; whereas preferred anions of inorganic acids are selected from : hydrogen halides, sulphates, phosphates, phosphonate and the like.
• Suitable salts can also be formed with cations or anions of amino acids selected from : lysine, arginine, ornithine, aspartic or glutamic acid, and the like.
• Preferred compounds of formula (I) in the form of paramagnetic amphiphilic complexes or salts thereof, according to the present invention are selected from :
• the present paramagnetic complexes or pharmaceutically acceptable salts thereof are suitable for the use as MRI contrast agent. Their use as d iagnostic agents in suitable pharmaceutical formulations, is therefore comprised within the scope of the present invention.
• the paramagnetic metal complexes according to the present invention show, advantageously, remarkably high relaxivity values, in particular when compared to known contrast agent commercially available and employed in diagnostic experiments.
• the relaxivity of the compounds of the invention is unexpectedly high when compared to some other well known compounds used as contrast agent in MRI, such as e.g . gadolinium-tetraazacyclododecanetetraacetic acid (Gd- DOTA).
• Gd- DOTA gadolinium-tetraazacyclododecanetetraacetic acid
• the amphiphilic complexes of the invention dissolve in aqueous solution and in human plasma and should be taken up more easily by th e ce l l than conventional gadolinium chelates, which are h ig hly hydrophilic.
• the invention relates to the use of an amphiphilic compound of formula (I) in the form of paramagnetic metal complex, or a pharmaceutical acceptable salt thereof, for the preparation of a MRI contrast agent.
• an amphiphilic compound of formula (I) in the form of paramagnetic metal complex, or a pharmaceutical acceptable salt thereof, for the preparation of a MRI contrast agent.
• paramagnetic complexes or pharmaceutically acceptable salt thereof can be conveniently used in the preparation of MRI contrast agents or formulations, particularly useful as blood pool agent, for the imaging of blood microcirculation in tumour, as contrast agent for angiography, as well as for the imaging of inflamed tissues in general.
• compositions comprisi ng the derivatives of formula (I) or pharmaceutical salts thereof, in the form of paramagnetic metal complex, in admixture with one or more physiologically acceptable excipients, diluents or solvents.
• physiologically acceptable excipients diluents or solvents.
• lipophilic and aqueous diluents and/or solvents are equally suitable for the compounds of the present invention, due to their amphiphilic nature.
• Pharmaceutical compositions can be suitably prepared for administration by any convenient route, e.g.
• compositions for oral, parenteral, topical (including ophthalmic and nasal) administration. They can also be formulated for administration by inhalation or insufflation (either through the mouth or nose). However, such compositions are preferably injectable compositions, adapted for use as contrast agent in imag ing tech niq ues, in particul ar for M R imag ing tech niq ues, and can conveniently be formulated in aqueous solutions or dispersions a t a physiologically acceptable pH, for parenteral use.
• the compounds of the present invention are particularly suited for the preparation of macromolecular aggregates such as micelles or liposomes, together with physiologically acceptable additives i.e. selected from surfactants amphiphatic compounds and/or stealth compounds, such as PEG.
• the formulations may comprise one or more derivatives of formula (I) in the form of a paramagnetic complex or a salt thereof, i n ad m ixtu re with one or more surfactant and/or amphipatic compounds.
• Micelles may be obtained by known techniques, for instance as described in WO97/00087, usually depending on the lipophilic characteristics of residue Y in formula (I).
• m i ce l les ca n be pre pa red i n a n y physiologically acceptable aqueous liquid carrier, such as water or saline, neat or buffered, and depending, e.g. , on the selected components, the dispersion can be achieved by gentle stirring or by homogenisation, microfluidification or sonication.
• the supramolecular aggregates of the invention can be collected, and even stored, as solids in a dry form, after treatment with known methods, e.g. by lyophilization or the like.
• the dry form (porous lumps or free flowing powder) is particularly convenient for long-term storage.
• the formulation can then be reconstituted before usage by dispersion of the lyophilized in a physiolog ical ly acceptable l iq u id carrier, thus obta in ing a suspension corresponding to the early formulation and directly usable as MRI contrast agent.
• the invention relates to a kit of parts comprising the above described lyophilized components and, separately, the liquid carrier.
• the lyophilized components may be stored under a dry, inert atmosphere whereas the carrier liq uid may fu rther contain isotonic add itives and other physiolog ical ly acceptable components, such as amino acids or the like.
• the invention comprise the process for the preparation of compounds of formula (I) by a process comprising at first the formation an adduct between the selected linker L and the diazepine moiety, followed by activation of the carboxylic function on the terminal side of the linker, followed by amidation with the selected Y group.
• the protecting groups, where present are eventually removed by standard techniques and the derivative is preferably optionally complexed with the selected paramagnetic metal.
• the adduct between the l in ker L a nd the diazepine moiety as starting material of the present process is obtained by reaction of a suitable nitro derivative, wh ich is a precursor of the selected l in ker moiety, with ⁇ , ⁇ '- dibenzylethylened iamine, which is the precursor of the diazepine core of the present derivatives, followed by reduction and functionalization of the nitro group, typically by hydrogenation and subsequent /V-alkylation under basic conditions.
• said adduct between the linker and the diazepine moiety ca n advantageously be prepared and used as building block for the preparation of a series of derivatives of formula (I) by varying the selected moiety Y.
• R 1_IV a re as a bove defi ned a n d L is the l i n ker com prisi n g a terminal carboxylic function
• step b) amidation reaction between the product of step b) and the Y group as above defined ;
• the process of the invention can be generally represented by the processes for the preparation of derivative 12a, wherein the compound 5 is the starting adduct, as indicated in the Scheme 1 below:
• the adduct 5 between the linker and the diazepine moiety is prepared by reaction of ⁇ /,/V'-dibenzyethylenediamine diacetate and an alcoholic solution of 6-nitrohexanoic acid methyl ester 1, in the presence of paraformaldehyde followed by: reduction and debenzylation of the n itro group 2, functionalization of the amine nitrogen atom 3 and selective cleavage of the terminal carboxylic group 4, as indicated in Scheme 2, herein below:
• step b) can be carried out e.g. according to proceed u res general ly known in organ ic chemistry for the activation of carboxylic functions, typically by reaction with a carboxyl activating agent, such as /V-hydroxysuccinimide (NHS) in the presence of a carbodiimide such as dicyclohexylcarbodiimide (DCC) or l-ethyl-3-(3-dimethylaminopropyl)- carbodiimide (EDC), in a molar ratio of at least 1 : 1 or preferably in a slight excess with respect to the starting material, e.g.
• a carboxyl activating agent such as /V-hydroxysuccinimide (NHS)
• a carbodiimide such as dicyclohexylcarbodiimide (DCC) or l-ethyl-3-(3-dimethylaminopropyl)- carbodiimide (EDC)
• step b) is conducted in the presence of /V-hydroxysuccinimide (N HS) and EDC in a molar ratio from 1 : 1 to 1 : 1.1 with respect to the starting material, and in the presence of CH 2 CI 2 .
• N HS /V-hydroxysuccinimide
• EDC EDC
• step c) an amidation reaction between the thus activated carboxylic terminal group of the linker L and the nitrogen atom of the selected Y residue for instance dibutylamine, generally in the presence of a diisopropylethylamine (DIPEA).
• DIPEA diisopropylethylamine
• the amidation reaction is carried out by dissolving the activated compound obtained after step b) in CHCI 3 and adding for instance dibutylamine and DIPEA in this order in a molar ratio from 1 : 1 to 1 : 1.7 with respect to the activated starting material.
• the solution is then stirred for a proper frame of time at a selected temperature, typically at roo m temperature (e.g.
• the thus formed amide product can be conveniently worked up, e.g. by washing with water and by evaporating the separated organic phase, generally under vacuum or distillation procedure. After purification, for instance by chromatography, the product of formula (I) is obtained in a protected form, e.g. preferably as tert-butyl ester derivative, in high yield (about 80%) and with a high degree of purity (about 95-99% HPLC).
• step d) the derivatives of formula (I) obtained in their carboxylic protected form, can be readily deprotected under conditions known in the art, and dependent for instance on the kind of protecting group actually employed in step a).
• protecting groups see "Greene's protective g rou ps in organ ic synthesis” Wiley 14 th Ed .
• the carboxylic function is protected as tert- butyl ester, and the deprotection is carried out under acid ic conditions, typically in the presence of trifluoroacetic acid (TFA) and an organic apolar solvent such as CH 2 CI 2 .
• TFA trifluoroacetic acid
• organic apolar solvent such as CH 2 CI 2 .
• the thus obtained compounds of formula (I) can suitably be reacted with a metal ion containing compound in order to obtain the corresponding metal complex derivatives.
• Said transformation is typically carried out by reaction with an inorganic or organic salt or oxide of the selected metal, operating in the presence of a solvent such as water or organic solvent, e.g. CHCI 3 or MeOH, or mixture thereof.
• Preferred counter ions are chloride or acetate, and preferred salts are: GdCI 3 , DyCI 3 , Gd(OAc) 3 or Dy(OAc) 3 , whereas preferred oxides are: Gd 2 0 3 or Dy 2 0 3 .
• the derivatives of formula (I) of the present invention in the form of a paramagnetic complex, are endowed with a particularly high degree of relaxivity (generally indicated as ri p ) and long lasting activity and stability, as demonstrated in the present Experimental part, Table I and Table II.
• Relaxivity (ri p ) is an intrinsic property of paramagnetic complexes which characterizes their ability to increase the nuclear magnetic relaxation rate of vicinal protons.
• High relaxation rates, i.e. high relaxivity values ensure increased contrast in the image, which makes possible to obtain diagnostic information in a short time frame.
• a long lasting activity and stability ensure both a visualization of the contrast agent for a proper frame of time, thus allowing a better and clear identifications of the regions analysed during the imaging method, and a proper excretion time from the body, thus avoiding unnecessary retaining of the contrast media within the sample.
• the present derivatives are particularly suitable for the use in the preparation of a diagnostic composition to be used in M RI techniq ues.
• the present invention provides a method for imaging of body regions comprising administering to a subject to be imaged a d iag nostical ly effective amount of a composition of the invention.
• said method is a MRI method comprising administering to a subject to be imaged a diagnostically effective amount of a composition of the invention comprisi ng a com pou nd of formu la (I) in the form of complex with a paramagnetic metal ion, wherein said metal ion is preferably selected from Gd 3+ and Dy 3+ .
• the present invention thus refers to a method for operating an imag ing system, comprising the steps of:
• the invention refers to a MRI method comprising the steps of:
• composition of the invention comprising a compound of formula (I) in the form of a paramagnetic complex, to a radiation frequency selected to excite nuclear spin transitions in a non-zero nuclear spin nuclei of said active substrate;
• the present invention advantageously provides a new class of diazepine of formula (I) and pharmaceutical salts thereof, obtainable by a straight full and convenient process, useful for the preparation of paramagnetic complexes, employable e.g. as contrast agent in MRI analysis. Even further, the relaxivity (ri p ) values of the present paramagnetic complexes are surprisingly high, thus rendering them a valid and convenient alternative to the prior art complexes as MRI contrast agents.
• the present complexes can be administrated as pharmaceutical compositions, showing a high relaxation rate and stability, thus allowing a low dosage.
• HPLC-ELSD ELSD 100% (area %); UV 89.1% (area %)
• HPLC-ELSD ELSD 100% (area %); UV 80.0% (area %)
• HPLC-ELSD ELSD 100% (area %); UV 89.0% (area %)
• Example 1.3c Preparation of compound 8c 6-[Bis[2-[(carboxy)methyl]amino]-6-[(13R)-10-hydroxy-10-oxido- 5,16-dioxo-13-(l-oxoesadecyl)oxy]-9,l l,15-trioxa-6-aza-10- phosphanonacos-l-yl]-tetrahydro-lH-l,4-diazepine-l,4(5H)- diacetic acid
• Example 1.4 C o m p l exa t i o n i n a q u eo u s m ed i a.
• the ligands 8(a-c) ( 1 eq ) was suspend ed i n H 2 0 (concentration 5%; starting pH 1-2) and dissolved at pH 6.5-7 by addition of 5% aq NaHC0 3 .
• a titrated solution of GdCI 3 (1 eq) was added in portions. The solution was stirred at room temperature and pH was maintained by addition of 5% aq NaHC0 3 .
• the complexation was monitored by HPLC-ELSD and with Xylenol Orange assay.
• the crude complexes were isolated by lyophil ization and were purified from salts by size exclusion chromatography to give 9(a-c).
• Example 1.4a Preparation of compound 9a
• Example 1.4b Preparation of compound 9b [6-[Bis[2-[(carboxy)methyl]amino]-6-[(13R)-10-hydroxy-10-oxido- 5,16-dioxo-13-(l-oxododecyl)oxy]-9,ll,15-trioxa-6-aza-10- phosphaeptacos-l-yl]-tetrahydro-lH-l,4-diazepine-l,4(5H)- diacetate(4-)]gadolinate( l-)]sodium
• the ligand 8b was complexed alternatively in organic media.
• Ligand 8b (0.506 g; 0.475 mmol) was dissolved in CHCI 3 (70 m L) and a solution of Gd(OAc) 3 0.011 M in 10 : 1 v/v MeOH/H 2 0 (29. 1 m L; 0.309 mmol ) was added in portions. Subsequently, the pH was adjusted to 7 using pyridine. The complexation was monitored by HPLC-ELSD and with Xylenol Orange assay and finally the solution was evaporated under reduced pressure.
• HPLC-ELSD ELSD 95.8 % (area %); UV 92.0 % (area %)
• HPLC-ELSD ELSD 99.0 % (area %); UV 99.5 % (area %)
• HPLC-ELSD ELSD 98.7 % (area %); UV 99.3 % (area %)
• HPLC-ELSD ELSD 82.4 % (area %).
• the compound 19 (9.52 g; 37.3 mmol) was dissolved in CH 3 CN (400 mL) then freshly grounded K 2 C0 3 (23.19 g; 167.8 mmol) and Na 2 S0 4 (15.88 g; 111.8 mmol) were added , t-butyl bromoacetate (24.6 mL; 167.8 mmol) was added and the orange mixture was stirred at 80 °C for 16 h . The salts were filtered off, and the filtrate was evaporated to resid ue that was dissolved in EtOAc (200 mL) and the solution washed with H 2 0 (3 x 70 mL) and saturated aq. NaCI (70 mL).
• Example 4.2b Preparation of compound 23b 6-[Bis[2-(l,l-dimethylethoxy)-2-oxoethyl]amino]-6-[(lR,4R)-4- [(dioctylamino)-carbonyl]cyclohexane-l-yl]tetrahydro-lH-l,4- diazepine-l,4(5H)-diacetic acid bis ( l,l-dimethylethyl)ester
• Example 4.4a Preparation of compound 25a
• MS is compatible with the structure Table I: r ip (mM ' V) for different Diazepine complexes, and for Gd- DOTA, Gd-HP-D03A, Gd-BT-D03A and Gd-BOPTA, determi ned i n different media at 0.47T, 25 °C.
• ri p values clearly demonstrate that the compounds of the present invention are endowed with a high relaxivity, as measured in water, HSA and even in plasma.
• known contrast agent broadly used in MRI analysis such as Gd-DOTA, Gd-BOPTA and Gd-BT- D03A
• the present derivatives show a remarked increased relaxivity, thus rendering them particularly suitable as MRI contrast agents.
• Ta ble II Stability at 37 °C of different diazepine complexes determined through r ip (mM 1 s "1 ) measurement in different media at 0.47T, 25 °C.
• Table II shows that the relaxivity values ri p of the amphiphilic complexes of the invention remain substantially stable over the time, thus providing a favourable lasting time during the experiment. In its turn, this means that the present amphiphilic complexes can be administered and detected during MRI experiments allowing a clear and exhaustive analysis of the image over a suitable frame of time.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Radiology & Medical Imaging (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47846054

Family Applications (1)

Country Status (7)

Cited By (4)

Families Citing this family (2)

Citations (5)

Family Cites Families (8)

• 2012
  • 2012-03-14 EP EP12159378.4A patent/EP2639227A1/en not_active Withdrawn
• 2013
  • 2013-03-13 US US14/384,414 patent/US9259491B2/en active Active
  • 2013-03-13 CA CA2863784A patent/CA2863784C/en active Active
  • 2013-03-13 JP JP2014561430A patent/JP6375231B2/ja active Active
  • 2013-03-13 EP EP13708844.9A patent/EP2834222B1/en active Active
  • 2013-03-13 WO PCT/EP2013/055094 patent/WO2013135750A1/en not_active Ceased
  • 2013-03-13 AU AU2013231301A patent/AU2013231301B2/en active Active
  • 2013-03-13 CN CN201380014181.7A patent/CN104203926B/zh active Active

Patent Citations (5)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events